ViaDerma Announces Significant 2024 Achievements and International Expansion
ViaDerma (OTC Pink: VDRM), a transdermal drug delivery and topical antibiotic products company, reports significant achievements in 2024. The company has expanded its workforce to 13 professionals, with 6 employees in the United States and 7 abroad, operating across seven countries. A major milestone includes the successful completion of a one-million-unit order to Nigeria, delivered in two shipments of 500,000 units each in August and October 2024. The company positions these achievements as groundwork for further expansion in 2025.
ViaDerma (OTC Pink: VDRM), un'azienda specializzata nella somministrazione transdermica di farmaci e nella produzione di antibiotici topici, ha riportato risultati significativi nel 2024. L'azienda ha ampliato il proprio team a 13 professionisti, con 6 dipendenti negli Stati Uniti e 7 all'estero, operando in sette paesi. Un traguardo importante include il completamento con successo di un ordine di un milione di unità per la Nigeria, consegnato in due spedizioni da 500.000 unità ciascuna ad agosto e ottobre 2024. L'azienda posiziona questi risultati come fondamenta per ulteriori espansioni nel 2025.
ViaDerma (OTC Pink: VDRM), una empresa dedicada a la entrega transdérmica de medicamentos y a productos antibióticos tópicos, informa sobre logros significativos en 2024. La compañía ha ampliado su plantilla a 13 profesionales, con 6 empleados en Estados Unidos y 7 en el extranjero, operando en siete países. Un hito importante incluye la finalización exitosa de un pedido de un millón de unidades para Nigeria, entregado en dos envíos de 500,000 unidades cada uno en agosto y octubre de 2024. La empresa considera estos logros como la base para una mayor expansión en 2025.
ViaDerma (OTC Pink: VDRM), 경피 약물 전달 및 국소 항생제 제품 회사가 2024년에 중요한 성과를 보고하였습니다. 이 회사는 13명의 전문가로 직원을 확장하였으며, 미국에 6명, 해외에 7명의 직원이 있고, 7개국에서 운영되고 있습니다. 주요 이정표는 나이지리아에 대한 100만 유닛 주문의 성공적인 완료를 포함합니다, 2024년 8월과 10월에 각각 500,000 유닛씩 두 번에 걸쳐 배송되었습니다. 이 회사는 이러한 성과를 2025년의 추가 확장을 위한 기초로 삼고 있습니다.
ViaDerma (OTC Pink: VDRM), une entreprise spécialisée dans la délivrance de médicaments par voie transdermique et la production de produits antibiotiques topiques, rapporte des réalisations significatives en 2024. L'entreprise a élargi son effectif à 13 professionnels, avec 6 employés aux États-Unis et 7 à l'étranger, opérant dans sept pays. Un jalon majeur comprend l'achèvement réussi d'une commande d'un million d'unités pour le Nigeria, livré en deux envois de 500 000 unités chacun en août et octobre 2024. L'entreprise positionne ces réalisations comme les fondations pour une expansion supplémentaire en 2025.
ViaDerma (OTC Pink: VDRM), ein Unternehmen für transdermale Medikamentenabgabe und topische Antibiotikaprodukte, berichtet über signifikante Erfolge im Jahr 2024. Das Unternehmen hat seine Belegschaft auf 13 Fachkräfte erweitert, mit 6 Mitarbeitern in den USA und 7 im Ausland, die in sieben Ländern tätig sind. Ein wichtiger Meilenstein ist der erfolgreiche Abschluss eines Auftrags über eine Million Einheiten für Nigeria, der in zwei Lieferungen zu je 500.000 Einheiten im August und Oktober 2024 erfolgt ist. Das Unternehmen betrachtet diese Erfolge als Grundlage für eine weitere Expansion im Jahr 2025.
- Successfully delivered 1 million units to Nigeria in two shipments
- Expanded workforce to 13 employees across seven countries
- Established international presence and distribution capabilities
- None.
LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a landmark year marked by significant global expansion and operational milestones. As the company continues its mission to deliver cutting-edge pharmaceutical products to underserved markets, 2024 has proven to be a transformative year.
ViaDerma’s expansion efforts in 2024 have led to a remarkable increase in personnel, with the team now totaling 13 dedicated professionals. This includes 6 employees based in the United States and 7 located abroad, spanning a total of seven countries, including the U.S., reflecting the company’s commitment to addressing healthcare needs on a global scale.
Furthermore, following the successful completion of the first shipment of 500,000 units to Nigeria in August—part of a one-million-unit order—ViaDerma fulfilled its promise by delivering a second shipment of 500,000 units in October. These achievements highlight the company’s ability to meet the growing demand for its innovative products and its dedication to fulfilling international commitments.
Dr. Christopher Otiko, CEO of ViaDerma, reflected on the year’s achievements and shared his vision for the future:
"2024 has been a truly transformative year in which ViaDerma laid substantial groundwork for a highly successful 2025. From humble beginnings as a small operation, we have grown into a company positioned to make a significant global impact. Our expansion into new markets and the successful delivery of product shipments are testaments to our unwavering commitment to innovation and accessibility. As we look to 2025, we are inspired by our progress and remain dedicated to building on this momentum, forging new partnerships, and expanding our reach to improve healthcare outcomes worldwide."
About ViaDerma, Inc.
ViaDerma, Inc. (OTC Pink: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
FAQ
How many units did ViaDerma (VDRM) ship to Nigeria in 2024?
How many employees does ViaDerma (VDRM) have as of 2024?
When did ViaDerma (VDRM) complete its Nigerian shipments in 2024?
